Wales Pharmaceutical Products Tenders & Contracts

Supply of Generic Drugs – Tablets and Capsules 2

This note formally records that the Transparency Notice was not published at the required stage of the process, due to a procedural oversight. Once identified, the issue was promptly escalated and corrective action was taken to ensure a notice is completed and published in line with the relevant regulatory and governance requirements. Internal processes and controls have since been reviewed to reduce the risk of this happening again. This medicine is a NICE approved product which is not currently available for procurement under the Bleeding Disorders Framework, managed by NHS England. In order for Welsh patients to obtain access to this medicine while a contract is being negotiated between the supplier and NHS England, this contract is being direct awarded to SOBI.

This note formally records that the Transparency Notice was not published at the required stage of the process, due to a procedural oversight. Once identified, the issue was promptly escalated and corrective action was taken to ensure a notice is completed and published in line with the relevant regulatory and governance requirements. Internal processes and controls have since been reviewed to reduce the risk of this happening again. This medicine is a NICE approved product which is not currently available for procurement under the Bleeding Disorders Framework, managed by NHS England. In order for Welsh patients to obtain access to this medicine while a contract is being negotiated between the supplier and NHS England, this contract is being direct awarded to SOBI.

Public Health Wales has a network of microbiology laboratories across Wales which provide diagnostic microbiology services to Health Boards as well as surveillance activities for the protection of Public Health. Sexual Health screening in Wales was rationalised in 2011 with testing provided from three sites: UHW / Imperial Park Unit 5 (IP5) in Newport, Ysbyty Glan Clwyd in Rhyl, and Singleton Hospital in Swansea. A Managed Service Contract (MSC) was put in place in 2013 and PHW plan to continue this regional approach and provide analysis of sexual health markers and related testing from the three sites with support and clinical input from Welsh Specialist Virology Centre, Cardiff. This contract is a short term contract for the supply of consumables for PHW owned equipment whilst a whilst a full procurement is conducted.

Award notice for the above CDMO services tender. Previous description as follows - The School of Medicine successfully applied for a UKRI grant to investigate in a randomised controlled trial (RCT), a new IMP (investigational medicinal product) called Triiodothyronine sulphate (T3S) in hypothyroid subjects with a gene difference in a thyroid related enzyme called deiodinase 2 (D2). We are looking for a CDMO to (i) Import and QP sign off T3S and matched placebo tablets obtained from Ardena, Pamplona, Spain who will manufacture these to GMP standards; (ii) over encapsulate commercially secured L-thyroxine (LT4 ) and matched placebo capsules; (iii) store T3S and matched placebo obtained from Ardena, and over encapsulated LT4 and matched placebo; (iv) label T3S, LT4 and respective placebo packs for distribution to trial subjects; (v) distribute T3S and matched placebo and over encapsulated LT4 and matched placebo packs to trial pharmacy (Royal Glamorgan Hospital, Wales).

Public Health Wales currently have Seegene platforms which are essential in providing a core part of NHS Wales COVID and respiratory testing, multiplex testing that includes Flu A, Flu B, RSV and SARS-CoV-2 and provide the largest multiplex testing capacity. The consumables included in this contract are essential for completing this testing and would have a significant impact on the service if not awarded.

Contract award details for the supply of Ustekinumab

Welsh Blood Service are awarding WBS-DCO-62192 HLA Rapid Typing Systems against NHS Blood and Transplant Framework 2024/S 000-037005

Welsh Blood Service are awarding WBS-DCO-62192 HLA Rapid Typing Systems against NHS Blood and Transplant Framework 2024/S 000-037005

The contract is for the provision of a Next Generation Sequencing (NGS) panel, associated reagents, technical support, training and related services to support diagnostic testing for Familial Hypercholesterolaemia (FH) within the All Wales Genomics Laboratory.Nonacus is the sole supplier capable of providing the required proprietary panel and associated services, which have been extensively validated within the existing diagnostic pathway. The solution is fully compatible with current laboratory infrastructure and includes ongoing technical support, quality assurance and contingency arrangements to support continuity of service delivery.The service supports approximately 600 diagnostic tests per annum, including initial and cascade testing, as part of the nationally commissioned All Wales Familial Hypercholesterolaemia service.

The contract is for the provision of a Next Generation Sequencing (NGS) panel, associated reagents, technical support, training and related services to support diagnostic testing for Familial Hypercholesterolaemia (FH) within the All Wales Genomics Laboratory. Nonacus is the sole supplier capable of providing the required proprietary panel and associated services, which have been extensively validated within the existing diagnostic pathway. The solution is fully compatible with current laboratory infrastructure and includes ongoing technical support, quality assurance and contingency arrangements to support continuity of service delivery. The service supports approximately 600 diagnostic tests per annum, including initial and cascade testing, as part of the nationally commissioned All Wales Familial Hypercholesterolaemia service.